An investigation on behalf of investors in Abeona Therapeutics Inc (NASDAQ: ABEO) shares over potential wrongdoing at Abeona Therapeutics Inc was announced.
San Diego, CA -- (SBWIRE) -- 07/20/2018 -- An investigation was announced for investors in shares of Abeona Therapeutics Inc (NASDAQ: ABEO) concerning potential breaches of fiduciary duties by certain officers and directors at Abeona Therapeutics Inc.
Investors who purchased shares of Abeona Therapeutics Inc (NASDAQ: ABEO) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Abeona Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Dalas, TX based Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc reported that its annual Total Revenue declined from $0.89 million in 2016 to $083 million in 2017 and that its Net Loss increased from $21.87 million in 2016 to $27.31 million in 2017.
Shares of Abeona Therapeutics Inc (NASDAQ: ABEO) declined from $21.70 per share in April 2018 to as low as $13.85 per share on July 19, 2018.
Those who purchased shares of Abeona Therapeutics Inc (NASDAQ:ABEO), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels